Get the Stockscreener App
1.62
1.82%
-0.03
Pre-market:
1.62
Eyenovia Inc stock is traded at $1.62, with a volume of 21,521.
It is down -1.82% in the last 24 hours and down -15.18% over the past month.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
See More
Previous Close:
$1.65
Open:
$1.6088
24h Volume:
21,521
Relative Volume:
0.07
Market Cap:
$3.39M
Revenue:
$31,800
Net Income/Loss:
$-37.83M
P/E Ratio:
-2.2817
EPS:
-0.71
Net Cash Flow:
$-30.64M
1W Performance:
-0.61%
1M Performance:
-15.18%
6M Performance:
-96.23%
1Y Performance:
-98.81%
1-Day Range:
$1.5767
$1.67
1-Week Range:
$1.52
$1.67
52-Week Range:
$1.43
$142.40
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
813-766-9539
Address
295 MADISON AVENUE,, NEW YORK, NY
Compare EYEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
1.62 | 3.39M | 31,800 | -37.83M | -30.64M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
Eyenovia, Inc. to Host Earnings Call - ACCESS Newswire
Eyenovia regains compliance with Nasdaq - MSN
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements - GlobeNewswire
Eyenovia Shares Surge After Regaining Nasdaq Compliance: What's Going On? - Benzinga
Eyenovia regains Nasdaq compliance, eyes strategic options By Investing.com - Investing.com Canada
Eyenovia regains Nasdaq compliance, eyes strategic options - Investing.com India
Eyenovia shareholders approve reverse stock split and additional stock reserve - MSN
Eyenovia Escapes Delisting Threat: What's Next for the Optejet Developer? - StockTitan
Eyenovia regains Nasdaq compliance with stock bid price By Investing.com - Investing.com Australia
Eyenovia regains Nasdaq compliance with stock bid price - Investing.com
Eyenovia, Inc. Announces Debt Restructuring, Including Amendment to Senior Secured Debt to Improve Liquidity - Vision Monday
Eyenovia defers debt payments to bolster liquidity By Investing.com - Investing.com Nigeria
Eyenovia announces debt restructuring, improving cash runway - MSN
Eyenovia, Inc. Announces Debt Restructuring Including - GlobeNewswire
Eyenovia defers loan payments, may convert debt to equity By Investing.com - Investing.com Canada
Eyenovia defers loan payments, may convert debt to equity - Investing.com India
Eyenovia defers debt payments to bolster liquidity - Investing.com India
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives - The Manila Times
Eyenovia, Inc. Announces Amendment to Senior Secured Convertible Debt to Enhance Liquidity and Support Optejet® Development - Nasdaq
Can This Biotech's Debt Restructuring Lead to a Strategic Sale? - StockTitan
FY2025 EPS Estimates for Eyenovia Boosted by HC Wainwright - Defense World
Eyenovia Inc’s (EYEN) Stock: A -58.29% Simple Moving Average for the Past 20 Days - The News Heater
Wainwright maintains neutral Eyenovia stock, $2 target - MSN
Wainwright maintains neutral Eyenovia stock, $2 target By Investing.com - Investing.com Canada
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - GlobeNewswire
The Attractiveness of Investing In Eyenovia Inc (EYEN) is Growing - Knox Daily
Eyenovia, Inc. Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - Marketscreener.com
Revolutionary Eye Drop Spray Shows Perfect Precision: Eyenovia's Game-Changing Solution for Millions - StockTitan
Eyenovia, Inc. Advances Development of User-Filled Optejet Device for Enhanced Ophthalmic Treatment - Nasdaq
Eyenovia enacts reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia
Eyenovia enacts reverse stock split to meet Nasdaq requirements - Investing.com
Eyenovia (NASDAQ:EYEN) Shares to Reverse Split on Monday, February 3rd - Defense World
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Eyenovia approves 1-for-80 reverse stock split; shares slip - MSN
Eyenovia Announces 1-for-80 Reverse Stock Split - GlobeNewswire
Major Shake-up at Eyenovia: Massive 80:1 Share Consolidation Coming February - StockTitan
Eyenovia, Inc. Approves 1-for-80 Reverse Stock Split to Regain Nasdaq Compliance - Nasdaq
Eyenovia shareholders approve reverse stock split and additional stock reserve By Investing.com - Investing.com Australia
Financial Survey: Mirum Pharmaceuticals (NASDAQ:MIRM) & Eyenovia (NASDAQ:EYEN) - Defense World
Eyenovia Inc Stock (EYEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eyenovia Inc Stock (EYEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rowe Michael M | Chief Executive Officer |
Aug 26 '24 |
Buy |
0.57 |
50,000 |
28,500 |
82,927 |
| Grant Stuart M. | 10% Owner |
Jul 02 '24 |
Buy |
0.66 |
1,515,151 |
1,000,000 |
10,914,153 |
| Grant Stuart M. | 10% Owner |
Mar 28 '24 |
Buy |
0.98 |
100,000 |
98,000 |
5,430,715 |
| Grant Stuart M. | 10% Owner |
Mar 19 '24 |
Buy |
1.23 |
50,000 |
61,500 |
5,330,715 |
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):